In an analysis of 31,717 cancer cases and 26,136 cancer-free controls from 13 genome-wide association studies, we observed large chromosomal abnormalities in a subset of clones in DNA obtained from blood or buccal samples. We observed mosaic abnormalities, either aneuploidy or copy-neutral loss of heterozygosity, of >2 Mb in size in autosomes of 517 individuals (0.89%), with abnormal cell proportions of between 7% and 95%. In cancer-free individuals, frequency increased with age, from 0.23% under 50 years to 1.91% between 75 and 79 years (P = 4.8 × 10 −8 ). Mosaic abnormalities were more frequent in individuals with solid tumors (0.97% versus 0.74% in cancer-free individuals; odds ratio (OR) = 1.25; P = 0.016), with stronger association with cases who had DNA collected before diagnosis or treatment (OR = 1.45; P = 0.0005). Detectable mosaicism was also more common in individuals for whom DNA was collected at least 1 year before diagnosis with leukemia compared to cancer-free individuals (OR = 35.4; P = 3.8 × 10 −11 ). These findings underscore the time-dependent nature of somatic events in the etiology of cancer and potentially other late-onset diseases.
A r t i c l e s
Classically, genetic mosaicism is defined as the coexistence of cells with two or more distinct karyotypes within an individual, resulting from a post-zygotic event during development that can occur in both somatic and germline cells 1, 2 . Errors in chromosomal duplication and subsequent transmission to daughter cells may lead to aneuploidy, the gain or loss of chromosomes or segments of chromosomes, and reciprocal gain and loss events that appear as copy-neutral loss of heterozygosity or acquired uniparental disomy. Somatic mosaicism has been established as a cause of miscarriage, birth defects, developmental delay and cancer [3] [4] [5] [6] [7] [8] [9] . Because mosaicism can be benign or may occur with diverse clinical phenotypes, there are no accurate estimates of its frequency in the general population 3, 6 . On rare occasions, the propensity to develop chromosomal abnormalities is inherited and leads to multiple phenotypic abnormalities, including cancer predisposition, as reported in families with mutations in the BUB1B and CEP57 genes 10, 11 . Recently, two groups have identified somatic mosaic mutations in IDH1 and IDH2 in tumors of individuals with Ollier disease and Maffucci syndrome 12, 13 , and another group has characterized somatic mosaicism of an HRAS mutation in an individual with urothelial cancer and epidermal nevus 14 . Recent work in a population of twins has suggested that the detection of somatic structural variants in blood increases with age and may be related to a reduction in blood cell clonality 15 . In this report, we broadly define mosaic chromosomal abnormalities as the presence of both normal karyotypes as well as those with large structural genomic events resulting in alteration of copy number or loss of heterozygosity in distinct and detectable subpopulations of cells, regardless of the clonal or developmental origin of the subpopulations.
Recently, we reported on 1,991 individuals from the Spanish Bladder Cancer Study (SBCS) population-based case-control study in which we had performed a genome-wide association study (GWAS) of adult-onset bladder cancer using DNA obtained from blood or buccal samples 16 .
The SNP array data generated for the GWAS were subsequently used to detect clonal mosaic abnormalities in the autosomes of 1.7% of study subjects, suggesting a higher frequency of these abnormalities in adults than was previously suspected. Even though somatic mosaicism has been implicated in several cancers, this study did not find a significant difference in the frequency of large chromosomal abnormalities between cases and controls. We used a computational algorithm to detect 42 large mosaic events involving two or more distinct clones in DNA extracted from blood or buccal samples, and we experimentally validated the findings using multiplex ligation-dependent probe amplification (MLPA) and microsatellite analysis (as well as FISH in one subset), establishing the robustness of the software detection method. We found a similar proportion of cells carrying each event for five of six events (four individuals with bladder cancer in whom three had one event and one had three separate events) in which it was possible to examine more than one tissue (whole blood and bladder mucosa), suggesting an early embryonic origin of the somatic mutation leading to the observed mosaic chromosomal abnormalities 16 .
RESULTS

Study overview
In this report, we extended our analysis of clonal mosaic abnormalities in the autosomes to 57,853 individuals (including those previously published 16 ). We tested 31,717 cancer cases and 26,136 cancer-free controls for evidence of mosaic abnormalities using genome-wide SNP array data generated as part of 13 distinct cancer GWAS drawn from 48 epidemiological case-control and case-cohort studies (Supplementary Table 1 ). DNA samples were extracted from blood or buccal samples using a variety of collection and extraction techniques and were genotyped using one or more Infinium Human SNP array from Illumina (including versions of Hap300, Hap240, Hap550, Hap610, Hap660, Hap1, Omni Express and Omni1; Detectable clonal mosaicism and its relationship to aging and cancer A r t i c l e s see Supplementary Data). Genotype clusters were empirically estimated in 45 batches to optimize accuracy while minimizing potential batch effects (Online Methods).
Detection of clonal mosaic events was based on assessment of allelic imbalance and copy-number changes. We used the B-allele frequency (BAF) measurement, derived from the ratio of probe values relative to the locations of the estimated genotype-specific clusters, for initial segmentation using the mosaic alteration detection (MAD) algorithm implemented in R Genomic Alteration Detection Analysis (R-GADA) software with modifications 17, 18 . The BAF and log 2 relative probe intensity ratio (LRR), which provides data on copy number, were used to classify each event as copy altering (gain or loss) or neutral (reciprocal gain and loss resulting in loss of heterozygosity, LOH) and to assign the proportions of abnormal (p) and normal (1-p) cells. Mosaic proportions were required to deviate from levels expected from constitutional (non-mosaic) changes in order to exclude homozygous chromosomal segments inherited identical by descent and non-mosaic instances of trisomy, monosomy and uniparental disomy. A minimum event size threshold was set to detect only clonal mosaic events greater than 2 Mb to minimize the false discovery of constitutional copynumber variants. Copy-neutral LOH and copy-loss events could be detected for mosaic proportions between 7% and 95% ( Fig. 1) , with sensitivity that was affected by the signal-to-noise ratio characteristic of each microarray assay and sample quality. There was reduced sensitivity to distinguish between copy-neutral LOH and copy-loss events for mosaic proportions less than 15% across the autosomes. The magnitude of BAF differences for single-copy gain events was one-third of the magnitude of that for copy-neutral LOH or copy-loss events, reducing the sensitivity for calling copy-gain events. As a result, single copy-gain events could only be reliably detected for mosaic proportions between 22% and 88%, with ambiguity in distinguishing copygain from copy-neutral LOH for mosaic proportions of less than 20%. Because DNA was obtained for the purpose of performing a GWAS, it was not possible to further explore the developmental and clonal characteristics of mosaic events detected in these individuals (for example, by studying DNA from fractionated blood and other tissue types or determining cell composition of buccal samples or effect of DNA collection and extraction methods on detection and accuracy of the estimation of mosaic proportions). We report only autosomal chromosomal abnormalities, as analysis of the sex chromosomes presents distinct technical and interpretative challenges.
We observed 681 mosaic segments of size greater than 2 Mb on 641 autosomal chromosomes in 517 individuals, for an overall frequency of individuals with detectable mosaicism of 0.87% (Tables 1 and 2) . The most frequent type of event observed was copy-neutral LOH (48.2%), whereas copy gains and copy losses constituted 15.1% and 34.8% of mosaic events, respectively ( Table 1) . A small proportion (1.9%) of mosaic chromosomes were complex, harboring more than one type of event. Of mosaic chromosomal events, 18.7% spanned the entire chromosome, including 62 complete trisomies, predominantly of chromosomes 8, 12 and 15. We found that 47.9% of mosaic chromosomal events began at a telomere and extended across some portion of the chromosomal arm ( Fig. 2 and Table 1 ). The majority of telomeric events were mosaic copy-neutral LOH (85.7%), most frequently on chromosome 9p ( Table 3) . The remaining mosaic chromosomal events were interstitial (31.5%), spanning neither telomere nor centromere, whereas an additional small proportion (1.8%) spanned the centromere or had more complex structure (for example, distinct events involving both telomeres but not the whole chromosome). The majority of interstitial events were mosaic copy loss (91.6%), which was most frequently observed within specific regions of chromosomes 13q and 20q (Fig. 2) . We observed 69 individuals (46 cancer cases and 23 cancer-free controls) with clonal mosaic events on multiple chromosomes. Among cancer-free individuals, the greatest number of mosaic chromosomal events observed was five, whereas six individuals with cancer had more than five events, including two individuals with gastric cancer who each had 20 events. A list of mosaic events with phenotype data is provided (Supplementary Data).
Mosaic abnormalities increase with age
The strongest predictor of mosaic autosomal abnormalities was age at DNA collection. We examined the effect of increased age on the frequency of mosaicism across all studies, which predominantly included individuals over the age of 50. The frequency of cancer-free individuals with detectable clonal mosaic events increased with age from 0.23% for those under 50 to 1.91% (P = 4.8 × 10 −8 ) for those between the ages of 75 and 79, with slightly higher frequencies occurring in individuals with cancer ( Fig. 3) . In individuals with early-onset cancer (under age 40), which constituted less than 5% of analyzed cases (for example, testicular cancer and osteogenic sarcoma), we did not observe an increase in mosaic abnormalities. Further studies are needed to investigate the relationship between mosaic abnormalities and cancer in children and young adults, particularly because of the strong association between mosaicism and many developmental disorders. There did We regressed the presence of detectable clonal mosaicism in 26,136 cancer-free individuals on age at DNA collection (in 5-year intervals), sex (male versus female), DNA source (buccal cells versus blood), smoking (ever versus never) and admixture coefficients for African and east Asian ancestry in a logistic model to identify additional factors that influence the frequency of detectable clonal mosaicism. The source of DNA was known for 87% of individuals, with 19% of samples derived from buccal cells and the remainder derived from blood. DNA source was not significantly associated with mosaicism (OR = 0.83, 95% confidence interval (CI) = 0.55-1.26; P = 0.39). In admixture analysis, 75% of subjects were determined to be of European ancestry, 9% of African ancestry and 16% of east Asian ancestry. Although power was limited, we determined that cancer-free individuals with African admixture were at a lower risk of being mosaic (OR = 0.43, 95% CI = 0.20-0.92; P = 0.03), but those with east Asian admixture were not (OR = 0.60, 95% CI = 0.32-1.15; P = 0.12). We did not observe an association between smoking and the frequency of mosaic abnormalities (OR = 1.04, 95% CI = 0.75-1.44; P = 0.81).
In 26,136 cancer-free controls and 23,093 cancer cases drawn from cancer sites that were non-sex specific and non-hematological (excluding 8,470 individuals with leukemia, lymphoma, multiple myeloma and cancers of the breast, endometrium, ovary, testis and prostate), we observed a higher frequency of males with mosaic abnormalities than females. In cancer-free individuals, we observed mosaic events in 0.56% of females and 0.87% of males (OR = 1.35, 95% CI = 0.98-1.88; P = 0.07); for individuals with cancer, we observed mosaic events in 0.79% of females and 1.21% of males (OR = 1.48, 95% CI = 1.08-2.03; P = 0.015); and, overall, 0.65% of females and 1.04% of males had mosaic events (OR = 1.42, 95% CI = 1.14-1.80; P = 0.002) in logistic models adjusted for cancer diagnosis (if applicable), age at DNA collection, ancestry, DNA source and smoking. These differences could be due to a true sex-specific effect akin to different sex-specific mutation and recombination rates 19 ; however, the complex and heterogeneous nature of the inclusion of individual studies and the differences in their entry and selection criteria could result in spurious associations. Although this observation was consistent across cancer types, it should be confirmed in additional studies that are better designed to address this question.
Mosaic abnormalities and cancer risk
To determine the relationship between detectable mosaic autosomal abnormalities and non-hematological cancers, we regressed the presence of detectable clonal mosaicism on cancer diagnosis, age, sex, DNA source, smoking and ancestry in a logistic model. We observed a modest increase in cancer risk for mosaic individuals (OR = 1.27, 95% CI = 1.05-1.52; P = 0.012) ( Table 2 and Supplementary  Table 2 ). Notable associations were observed in stratified analyses of lung (OR = 1.56, 95% CI = 1.18-2.08; P = 0.002) and kidney (OR = 1.98, 95% CI = 1.27-3.06; P = 0.002) cancers, both of which are tobacco-associated malignancies. However, no cancer site-specific associations were observed for bladder, esophageal, stomach and pancreatic cancers, which are also typically associated with tobacco use. There was no significant association in non-hematological cancer cases overall between smoking (ever versus never) and the In an analysis of the subset of 14,050 individuals with cancer for whom it was possible to determine that DNA was likely obtained before or at the time of diagnosis and before treatment with radiation or chemotherapy for a primary tumor (designated as likely untreated), we observed a stronger association between mosaic abnormalities and diagnosis with non-hematological cancer (OR = 1.45, 95% CI = 1.18-1.80; P = 0.0005). The associations for lung and kidney cancers were also increased in significance ( Table 2) . It is notable that the evidence for association with non-hematological cancer was diminished in individuals who were potentially treated (OR = 1.03 ,   1   0  10 20 30 40 50 60 70 80  90  100 110 120  130  140  150  160  170  180  19 0 20 0 21 0 22 0 23  0 24  0   2   0  10  20  30  40  50  60  70  80  90  10  0  11  0  12   0  13 0  14 0  15 0  16 0  17 0  18 0  19 0  20 0  21 0  22 0  23 0  24 0   3   0  10  20  30  40  50  60  70  80  90  100  110  120  130  140  150  160  170  180 60 70 80  90  100 110 120  130  140  150  160  170  180  19 0 20 0 21 0 22 0 23  0 24  0   2   0  10  20  30  40  50  60  70  80  90  10  0  11  0  12  0  13 0  14 0  15 0  16 0  17 0  18 0  19 0  20 0  21 0  22 0  23 0  24 0   3   0  10  20  30  40  50  60  70  80  90  100  110  120  130  140  150  160  170  180 Del, deletion; CN LOH, copy-neutral loss of heterozygosity.
npg
A r t i c l e s 95% CI = 0.81-1.30; P = 0.80). We had approached this analysis with the hypothesis that there could be an increased frequency in detectable clonal mosaicism in non-hematological cancers induced by chemotherapy or radiotherapy. Thus, the observation that the frequency of mosaic events was reduced by treatment to virtually the same level seen in the cancer-free population was unexpected. Although this observed attenuation could have many explanations (for example, related to the diagnosis and treatment of a solid tumor leading to a decrease in the populations of cells with mosaic alteration), we had limited capacity to model and control for treatment effects, as many of the studies did not provide any information on treatment or only provided incomplete, retrospective ascertainment of the specifics. Although many of the participating studies were prospectively ascertained cohorts, DNA collection often occurred after cancer diagnosis. Additional studies are needed in prospectively ascertained cohorts, in addition to longitudinal studies in which multiple DNA samples are collected before and after diagnosis, in order to explore the effects of treatment and disease on mosaicism. For the 43 individuals with hematological cancers for whom DNA was obtained at least 1 year before diagnosis, the frequency of detectable clonal mosaicism was 20% for those with myeloid leukemia and 22% for those with lymphocytic leukemia (predominantly chronic lymphocytic leukemia; Table 2 ) compared to 0.74% in 26,136 cancerfree controls (overall OR = 35.4, 95% CI = 14.7-76.6; Fisher's exact P = 3.8 × 10 −11 ). Of the eight mosaic individuals with leukemia for whom DNA samples were collected at least 1 year before diagnosis, four were diagnosed with chronic lymphocytic leukemia (CLL), of whom two had a mosaic deletion in a region of chromosome 13q14 previously described to be deleted in CLL 20 . DNA was obtained more than 5 years before diagnosis for six mosaic individuals, with the longest interval being 14 years, suggesting that detectable clonal mosaicism could be a marker of hematological cancer or its precursors, such as monoclonal B cell lymphocytosis (MBL) for CLL and myelodysplastic syndrome for acute myelogenous leukemia. Recent work shows that the majority of individuals with MBL have monoor biallelic 13q14 abnormalities 21 . However, further studies will be needed, preferably with serial sampling before and after diagnosis, to investigate the predictive nature of detectable clonal mosaicism, especially for events involving regions of chromosomes 13 and 20 in leukemia risk 20 .
We further explored the four most recurrently altered regions , those detected in more than 20 individuals, which also harbored well-known cancer genes (as noted in the Catalogue of Somatic Mutations in Cancer (COSMIC) 22 and Mitelman databases; these were on chromosomes 9p (copy-neutral LOH), 13q (deletion), 14 (copy-neutral LOH) and 20q (deletion) ( Table 3) . Notably, the most recurrent mosaic events were observed in cancer-free individuals as well as across multiple individuals with solid tumors. We observed a comparable frequency of mosaic events in non-hematologic cancer cases and cancer-free controls for three of the regions, whereas chromosome 14 copy-neutral LOH abnormalities were more frequent in non-hematological cancer cases (OR = 3.32, 95% CI = 1.42-9.00, Fisher's exact P = 0.003), particularly in individuals with bladder or kidney cancer. Copy-neutral LOH in this region of chromosome 14 has been associated with increased susceptibility to sporadic cancers, and this region includes imprinted genes, such as the tumor suppressing non-coding RNA, MEG3 (encoding maternally expressed gene 3) 8, 23 . The recurrent segmental deletion of 13q14 was observed in 5 leukemia cases but also in 18 individuals with solid tumors (9 with lung cancer and 4 with prostate cancer) and in 10 cancer-free individuals. This region includes the tumor suppressor gene DLEU7 (encoding deleted in leukemia 7) and the related genes, DLEU1 and DLEU2, the latter of which encodes two microRNAs within one of its introns (miR-15a and miR-16-1) [24] [25] [26] . The retinoblastoma gene RB1 was also included within the affected region in a subset of cases with a mosaic deletion of 13q14. It cannot be ruled out that these individuals have either undiagnosed CLL or MBL. We observed the 20q deletion in two individuals with myeloid leukemia, as has been described previously 27 , but also in cancer-free individuals and in individuals with solid tumors.
The accuracy of our software methods in detecting clonal mosaic abnormalities has previously been addressed, and we were able to validate 100% of 42 events in 34 individuals from the Spanish Bladder Cancer Study using confirmatory cytogenetic assays 16 ( Supplementary Fig. 3) . We also performed a comparison of mosaic events in samples from the EAGLE and PLCO lung cancer studies, which were independently analyzed as part of the Gene-Environment Association Studies (GENEVA) consortium report on mosaic events 28 . A total of 83 mosaic events in individuals from the Environment and Genetics in Lung Cancer Etiology Study (EAGLE) and Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial (PLCO) lung cancer studies were detected in common, 20 additional events of less than 2 Mb in size and 8 events of greater than 2 Mb in size were detected by GENEVA and not by our study, and we detected 20 additional events (of >2 Mb in size) that were not detected by GENEVA. Although additional cytogenetic or molecular validation was not performed, neither method detected notable false positive events, according to manual review of the data. The concordance rate was 75% if considering events of >2 Mb in size (the cutoff for this analysis) or 63% if considering all events, both of which are considerably better than the 25-50% concordance rates observed across CNV detection methods [29] [30] [31] . Our method is more conservative in the size of events detected, whereas the GENEVA method is more conservative with respect to sample quality but provides calls for smaller events when assay quality is sufficient. Better approaches are needed to accurately characterize events of smaller size as either mosaic or constitutional and to estimate their frequency. Further improvements to data normalization, segmentation and event classification methods will also likely reduce false negative detection rates.
DISCUSSION
Our study has important implications for the design and analysis of molecular epidemiology studies in cancer, as well as the somatic characterization of cancer genomes, such as The Cancer Genome Atlas 32 npg A r t i c l e s DNA for somatic alterations, such as detectable clonal mosaicism. Otherwise, comparisons between "somatic cells" (used as a surrogate for germline) and tumors may result in implausible somatic changes (for example, large gains of heterozygosity), and it may be impossible to determine whether somatic events predate changes secondary to driver mutations. Because the method to detect mosaic events with next-generation sequencing technologies is neither routine nor well understood, for the near future, it may be prudent to continue to use SNP microarrays for such analyses. As a result of the increased frequency of detectable clonal mosaicism with age, this will be particularly important for the analysis of epithelial cancers, which characteristically occur in the older population. For future large-scale GWAS in prospective studies, it may be wise to consider analyzing the earliest DNA samples before diagnosis and to consider the time from collection to diagnosis in the analysis of longitudinally collected biospecimens. We have extended our initial observation that detectable clonal mosaicism of the autosomes is present in the population with unexpectedly high frequency, particularly in the aging genome. A recent study of detectable clonal mosaicism in twins reported an increase in frequency with age and suggested that this could lead to a less diverse blood cell population and immune system 15 . These emerging data identify a number of critical issues in the mechanisms underlying a possible shift in the repertoire of clones with large structural abnormalities. For example, cells with abnormal karyotypes could have an early developmental origin in which a somatic event in a single stem cell progenitor during embryogenesis could become apparent when cellular diversity decreases with age and cell populations become increasingly oligoclonal. Higher rates of detectable clonal mosaicism in older cancer-free individuals could also be due to increased rates of somatic mutation or diminished capacity for genomic maintenance, such as with telomere attrition 34 , leading to proliferation of somatically altered cell populations. A survival bottleneck of cellular progenitors could also lead to observable mosaic alterations that were previously below the threshold of detection but subsequently expanded due to positive selection. Further work is required to unravel the underlying mechanisms that result in mosaic abnormalities, particularly in respect to how and when altered clones are created, tissue specificity and the timing of expansion of distinct populations of cells with age. Finally, these findings underscore the importance of considering the role and time-dependent nature of somatic events in the etiology of cancer and other late-onset diseases.
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Methods and any associated references are available in the online version of the paper.
Note: Supplementary information is available in the online version of the paper.
(0 if subject had DNA collected at least 1 year before diagnosis of their first cancer or before treatment with chemotherapy or radiation could have occurred and 1 otherwise). This latter variable is highly heuristic due to the lack of available data on treatment. It is intentionally conservative, in the sense that many subjects will be listed as possibly treated, even though it is unlikely that they would have had sufficient time or stage/grade of cancer to warrant treatment with radiation or chemotherapy.
When modeling mosaicism in controls, adjustments terms were included for age at DNA collection, sex, study, DNA source, smoking and ancestry. When modeling the relationships between mosaicism and sex, individuals diagnosed with sex-specific cancer sites were excluded. In models to determine the association between mosaicism and articular sex-specific cancer sites, only controls relevant to the cancer site were included in the model (for example, only male controls were used in models of prostate cancer cases). Models of mosaicism for early-onset cancer sites (testis and osteogenic sarcoma) excluded controls over the age of 45.
